Resveratrol

Evidence posture

Human evidence is heterogeneous and low-certainty for many cardiometabolic outcomes; anti-aging or longevity claims are not established.

What the evidence supports

NCCIH summarizes low-certainty evidence suggesting resveratrol may influence fasting glucose or blood pressure in some people with type 2 diabetes, while other outcomes are neutral and more research is needed.

Studied context

Trials often use concentrated resveratrol doses far above typical dietary exposure. Dose, formulation, health status, and outcome strongly affect interpretation.

Safety context

Oral resveratrol appears generally tolerated in available studies, but it may interact with anticoagulant or antiplatelet drugs and supplements.

Product directness

COLLAGEN COMPLEX and NOURISH+ list resveratrol but do not publish a trial-matched dose. Anti-aging, metabolic, or cardiovascular outcomes cannot be inferred from ingredient presence.

Products that list this ingredient/category

Primary and authoritative sources

Type 2 Diabetes and Dietary Supplements: What the Science Says — Resveratrol (NCCIH)
Resveratrol bioavailability and toxicity in humans — PMID 20013887 (PubMed review)

Important: Ingredient-level evidence is not proof that a finished product has the same effect. Dose, form, population, duration, and formulation must match.

For informational purposes only; not individualized medical advice.